NCT01243346View on ClinicalTrials.gov

Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
D842-related Mutant GIST
Interventions
DRUG

Crenolanib besylate (CP-868,596-26), Dose: 140mg BID

Highly potent inhibitor of both PDGFR receptors alpha and beta

Trial Locations (2)

97239-3098

Knight Cancer Institute, Oregon Health and Science University, Portland

19111-2497

Fox Chase Cancer Center, Philadelphia

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY